Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy

被引:54
作者
Irace, Concetta [1 ]
Casciaro, Francesco [1 ]
Scavelli, Faustina Barbara [2 ]
Oliverio, Rosa [2 ]
Cutruzzola, Antonio [1 ]
Cortese, Claudio [3 ]
Gnasso, Agostino [2 ]
机构
[1] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Viale Europa, I-88100 Catanzaro, Italy
[2] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Viale Europa, I-88100 Catanzaro, Italy
[3] Tor Vergata Univ, Dept Expt Med & Surg, Via Orazio Raimondo 18, Rome, Italy
关键词
Empagliflozin; Blood viscosity; Rheology; Shear stress; Intima-plus media thickness; INTIMA-MEDIA THICKNESS; CARDIOVASCULAR OUTCOMES; SGLT-2; INHIBITORS; CAROTID-ARTERY; RISK; PROGRESSION; STROKE; PLAQUE; DAPAGLIFLOZIN; ASSOCIATION;
D O I
10.1186/s12933-018-0695-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cardiovascular protection following empagliflozin therapy is not entirely attributable to the glucose lowering effect. Increased hematocrit might influence the shear stress that is the main force acting on the endothelium, regulating its anti-atherogenic function. Objective: We designed the study with the aim of investigating the effect of empagliflozin on blood viscosity and shear stress in the carotid arteries. A secondary endpoint was the effect of empagliflozin on carotid artery wall thickness. Methods: The study was a non-randomized, open, prospective cohort study including 35 type 2 diabetic outpatients who were offered empagliflozin or incretin-based therapy (7 liraglutide, 8 sitagliptin) in combination with insulin and metformin. Blood viscosity, shear stress and carotid wall thickness were measured at baseline and at 1 and 3 months of treatment. Blood viscosity was measured with a viscometer, and shear stress was calculated using a validated formula. Intima-media thickness (IMT) of the carotid artery was detected by ultrasound and was measured with dedicated software. Results: Blood viscosity (4.87 +/- 0.57 vs 5.32 +/- 0.66 cP, p < 0.02) and shear stress significantly increased in the Empagliflozin group while no change was detected in the Control group (4.66 +/- 0.56 vs 4.98 +/- 0.73 cP, p = NS). IMT significantly decreased in the Empagliflozin group after 1 and 3 months (baseline: 831 +/- 156, 1-month 793 +/- 150, 3-month 766 +/- 127 mu m; p < 0.0001), while in the liraglutide group, IMT significantly decreased only after 3 months (baseline 879 +/- 120; 1-month 861 +/- 163; 3-month 802 +/- 114 mu m; p < 0.001). In the sitagliptin group, IMT remained almost unchanged (baseline 901 +/- 135; 1-month 902 +/- 129; 3-month 880 +/- 140 mu m; p = NS). Conclusions: This study is the first to describe a direct effect of empagliflozin on blood viscosity and wall shear stress. Furthermore, IMT was markedly reduced early on in the Empagliflozin group.
引用
收藏
页数:9
相关论文
共 43 条
  • [41] Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study
    Tanaka, Atsushi
    Murohara, Toyoaki
    Taguchi, Isao
    Eguchi, Kazuo
    Suzuki, Makoto
    Kitakaze, Masafumi
    Sato, Yasunori
    Ishizu, Tomoko
    Higashi, Yukihito
    Yamada, Hirotsugu
    Nanasato, Mamoru
    Shimabukuro, Michio
    Teragawa, Hiroki
    Ueda, Shinichiro
    Kodera, Satoshi
    Matsuhisa, Munehide
    Kadokami, Toshiaki
    Kario, Kazuomi
    Nishio, Yoshihiko
    Inoue, Teruo
    Maemura, Koji
    Oyama, Jun-ichi
    Ohishi, Mitsuru
    Sata, Masataka
    Tomiyama, Hirofumi
    Node, Koichi
    [J]. CARDIOVASCULAR DIABETOLOGY, 2016, 15
  • [42] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) : 2117 - 2128
  • [43] SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
    Zou, Honghong
    Zhou, Baoqin
    Xu, Gaosi
    [J]. CARDIOVASCULAR DIABETOLOGY, 2017, 16